6Shaikh AS, Somani RS. Animal models and biomarkers of neuropathy in diabetic rodents [ J ]. Indian J Pharmacol,2010 ;42 ( 3 ) : 129-34.
7Schwartz S, Etropolski M, Shapiro DY,et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy : results of a randomized-withdrawal, placebo-controlled trial [ J ] . Curr Med Res Opin,2011 ;27(1 ) :151-62.
8Perkins BA, Dholasania A, Buchanan RA, et al. Short-term metabolic change is associated with improvement in measures of diabetic neuropathy:a 1-year placebo cohort analysis[ J]. Diabet Med,2010;27( 11 ) : 1271-9.
9Wu Z, Mata M ,Fink DJ. Prevention of diabetic neuropathy by regulatable expression of HSV-mediated erythropoietin [ J ]. Mol Ther,2011 ; 19 ( 2 ) : 310-7.
二级参考文献16
1Schnyder G,Sawhney N,Whisenant B,et al.Common femoral artery anatomy is influenced by demographics and comorbidity:Implications for cardiac and peripheral invasive studies.Catheter Cardiovasc Interv,2001,53:289-295.
2Singh NP,Pgyazhendhi V,Das AK,et al.Clinical and laboratory profile of diabetes in elderly.J Indian Med Assoc,1999,97:124-128.
3Bhardwaj SK,Sandhu SK,Sharma P,et al.Impact of diabetes on CNS:role of signal transduction cascade. Brain Res Bull,1999,49:155-162.
4Shalitin S,Josefsberg Z,Lilos P,et al.Beside scoring procedure for the diagnosis of diabetic neuropathy in young patients with type 1 diabetes.J Pediatr Endocrinol Metab,2002,15:613-620.
5Isomaa B,Henricsson M,Almgren P,et al.The metabolic syndrome influences the risk factor of chronic complications in patients with type 2 diabetes.Diabetologia,2001,44:1148-1154.
6Perkins BA,Green DA,Bril V.Glycemia control is related to the morphological severity of diabetic sensorimotor polyneuropathy.Diabetes Care,2001,24:748-752.
7Estacio RO,Jeffers BW,Gifford N,et al.Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes.Diabetes Care,2000(Suppl 2):B54-B64.
9Akbar DH,Mira SA,Zawawi TH,et al.Subclinical diabetic neuropathy:a common complication in Saudi diabetes.Saudi Med J,2000,21:433-437.
10Collin HL,Niskanen L,Unsitupa M,et al.Oral symptoms and signs in elderly patient with type 2 diabetes mellitus.Oral Surg Oral Med Oral Pathol Oral Radiol Endod,2000,90:299-305.
2Qaseem A> Humphrey L L,Sweet D E> et al. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians[J]. Ann Intern Med,2012;156 (3): 218-231.
3Greco D,Gambina F,Maggio F. Ophthalmoplegia in diabetes mellitus: a retrospective study[j]. Acta Diabetol, 2009:46(1):23-26.
4Tesfaye S, Boulton A J M, Dyck P J, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments[J]. Diabetes Care, 2010:33(10): 2285-2293.
5Volarevic V,Arsenijevic N, Lukic M L, et al.Concise review: mesenchymal stem cell treatment of the complications of diabetes mellitus[J]. Stem Cells,2011;29(1):5-10.
6Vincent A M, Callaghan B C,Smith A L, et al. Diabetic neuropathy: cellular mechanisms as therapeutic targets[J]. Nat Rev Neurol, 2011;7(10):573-583.
